Mainz Biomed Statistics
Total Valuation
Mainz Biomed has a market cap or net worth of $10.68 million. The enterprise value is $19.35 million.
Important Dates
The next estimated earnings date is Tuesday, April 15, 2025, before market open.
| Earnings Date | Apr 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mainz Biomed has 3.37 million shares outstanding. The number of shares has decreased by -96.58% in one year.
| Current Share Class | 3.37M |
| Shares Outstanding | 3.37M |
| Shares Change (YoY) | -96.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.60% |
| Owned by Institutions (%) | 1.39% |
| Float | 3.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.95 |
| Forward PS | 9.10 |
| PB Ratio | -2.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.50 |
Financial Efficiency
Return on equity (ROE) is -4,333.72% and return on invested capital (ROIC) is -154.40%.
| Return on Equity (ROE) | -4,333.72% |
| Return on Assets (ROA) | -99.24% |
| Return on Invested Capital (ROIC) | -154.40% |
| Return on Capital Employed (ROCE) | 1,412.79% |
| Revenue Per Employee | $12,918 |
| Profits Per Employee | -$316,998 |
| Employee Count | 71 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.54% in the last 52 weeks. The beta is 0.33, so Mainz Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -92.54% |
| 50-Day Moving Average | 5.35 |
| 200-Day Moving Average | 10.06 |
| Relative Strength Index (RSI) | 30.55 |
| Average Volume (20 Days) | 177,285 |
Short Selling Information
The latest short interest is 128,497, so 3.81% of the outstanding shares have been sold short.
| Short Interest | 128,497 |
| Short Previous Month | 79,743 |
| Short % of Shares Out | 3.81% |
| Short % of Float | 4.21% |
| Short Ratio (days to cover) | 0.30 |
Income Statement
In the last 12 months, Mainz Biomed had revenue of $917,203 and -$22.51 million in losses. Loss per share was -$44.98.
| Revenue | 917,203 |
| Gross Profit | 540,958 |
| Operating Income | -22.04M |
| Pretax Income | -26.30M |
| Net Income | -22.51M |
| EBITDA | -21.59M |
| EBIT | -22.04M |
| Loss Per Share | -$44.98 |
Full Income StatementBalance Sheet
The company has $977,764 in cash and $8.27 million in debt, giving a net cash position of -$7.29 million or -$2.16 per share.
| Cash & Cash Equivalents | 977,764 |
| Total Debt | 8.27M |
| Net Cash | -7.29M |
| Net Cash Per Share | -$2.16 |
| Equity (Book Value) | -4.14M |
| Book Value Per Share | -6.47 |
| Working Capital | -7.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.31 million and capital expenditures -$294,946, giving a free cash flow of -$19.60 million.
| Operating Cash Flow | -19.31M |
| Capital Expenditures | -294,946 |
| Free Cash Flow | -19.60M |
| FCF Per Share | -$5.82 |
Full Cash Flow StatementMargins
| Gross Margin | 58.98% |
| Operating Margin | -2,402.78% |
| Pretax Margin | -2,453.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mainz Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 96.58% |
| Shareholder Yield | n/a |
| Earnings Yield | -186.61% |
| FCF Yield | -162.51% |
Analyst Forecast
The average price target for Mainz Biomed is $14.00, which is 341.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.00 |
| Price Target Difference | 341.64% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 142.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 3, 2024. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Dec 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
Mainz Biomed has an Altman Z-Score of -21.37 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.37 |
| Piotroski F-Score | 4 |